ArticleTransfusion2025
Several features of newborns following intrauterine intravascular blood transfusion for fetal hemolytic disease caused by anti-D alloimmunization.
Article in Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly detection and intervention for fetal hemolytic disease are essential to prevent severe complications. This study evaluates the antenatal and postnatal clinical and laboratory characteristics of newborns who underwent intrauterine intravascular transfusion due to anti-D-induced hemolytic disease. STUDY DESIGN AND
methodsTwenty newborns who received intrauterine transfusions between 18 and 35 weeks of gestation were included. Data on maternal history, transfusion frequency, birth anthropometrics, ABO blood group, D typing, laboratory findings, morbidities, and hospitalization duration were analyzed.
resultsThirteen cases (65%) had anti-D antibody titers ≥1:1024. Intrauterine transfusions were administered once in 55% of cases, twice in 15%, and three or more times in 30%, with a mean gestational age of 29.6 ± 2.3 weeks. The mean birth weight and gestational age were 2478.7 ± 222.03 g and 35.6 ± 2.08 weeks, respectively. Severe hyperbilirubinemia requiring treatment was present in 50% of newborns, while 50% exhibited anemia-related complications. Hypoxic-ischemic encephalopathy and intracranial hemorrhage were observed in 55% and 45% of cases, respectively. Exchange transfusions were required in 65% (once) and 10% (twice) of cases. All newborns received standard hemolytic disease treatments, including high-intensity phototherapy (94.3 ± 22.4 h), infusion therapy (packed red cell transfusions, 10 mL/kg, 8 ± 2 times), and intravenous immunoglobulin (0.5-1 g/kg, 6 ± 1 times).
conclusionNewborns with anti-D-alloimmunization-induced hemolytic disease requiring intrauterine transfusion demand intensive neonatal care to manage anemia, hyperbilirubinemia, hypoxic-ischemic encephalopathy, and intracranial hemorrhage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.